The vaccine will be developed using Enesi's ImplaVax platform to create a DNA vaccine in a solid-dose implant format for transcutaneous delivery via a needle-free device. The novel DNA vaccine construct was developed by researchers at the University of Adelaide. This combination is expected to enhance the vaccine's efficacy, thermal stability and allow for safe, rapid vaccination of target populations that are geographically and economically disadvantaged.

The collaboration, valued at $1 million, will advance the development of the thermostable, solid-dose Zika virus DNA vaccine to a phase I clinical trial.

The program is being funded by the Australian government's Biomedical Translation Bridge, Enesi Pharma, the Hospital Research Foundation, Adelaide Enterprise Commercial Accelerator Scheme, and the University of Adelaide Faculty of Health and Medical Sciences.

NIH establishes Centers for Research in Emerging Infectious Diseases
The National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health (NIH), has awarded 11 grants for a first-year...

J&J's Ebola vaccine approved by EU
Johnson & Johnson announced that the European Commission granted marketing authorization for its Janssen Pharmaceutical Ebola vaccine regimen for...